BioSpace News Archive

Aligos Therapeutics, headquartered in South San Francisco, halted the development of ALG-020572, which was being developed in patients with chronic hepatitis B (CHB).

Less than two months after joining the executive committee of the Voyager Therapeutics Board of Directors, Alfred W. Sandrock Jr. has been named CEO of the company.

Merck’s Keytruda has become an approved treatment for yet another indication: unresectable or metastatic advanced endometrial carcinoma. Know more about it here.

In the interim, Daniel Faga will take the helm as president and CEO after Hamza Suria let go of his executive functions.

Depressive disorder is associated with longer in-hospital length of stay, higher rates of medical complications, and increased healthcare costs for patients undergoing reverse shoulder arthroplasty for the treatment of glenohumeral osteoarthritis, according to a large-scale study presented at the 2022 Annual Meeting of the American Academy of Orthopaedic Surgeons.

Millions of athletes worldwide have been wrestling with the challenges of working out under stay-at-home orders and evolving COVID-19 mandates and concerned about wearing a face mask if training in public or outside.

Halozyme Therapeutics, Inc. announced that data from argenx’s Phase 3 ADAPT-SC study evaluating subcutaneous efgartigimod for the treatment of generalized myasthenia gravis achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical non-inferiority to VYVGART® intravenous formulation in gMG patients.

Biovica, active in cancer diagnostics, announced that positive results on CDK 4/6 standard therapy from a clinical study at the University of Nebraska Medical Center and Washington University School of Medicine, US, is published in npj Breast Cancer, a Nature open access journal dedicated to publishing the finest research on breast cancer research and treatment.

RadNet, Inc. announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company Spring 2022 Conference on Thursday, March 24th at 01:00 p.m. Eastern Time.

Evaxion Biotech A/S announced the fourth quarter and full-year 2021 financial results and provided an operational update.